Browse by business need


Rapid changes in the pharmaceutical and drug development fields require a dedicated team of experts. Our consulting experience includes applying actuarial principles to health economics challenges for both pharmaceuticals and medical devices and builds on the support of in-house health economists and clinicians. Our areas of research draw on real-world evidence and outcomes data, which includes quantifying the financial burden of antibiotic resistance and measuring value of novel antibiotics, sharing financial risk of new health technologies, and designing alternative reimbursement and evaluation models for high cost drugs targeting rare diseases and genetic disorders. We can assist clients with understanding their value proposition from a payer perspective and highlighting the implications of demographic change on the value proposition and financial risk-sharing arrangements.